Articles related to ANTIDEPRESSANTS

Stay informed about the latest research on factors influencing COVID-19 outcomes. Learn more about how these findings could influence your approach to patient care.

Discover how Exxua, the newly FDA-approved antidepressant, could be a game-changer in treating major depressive disorder, backed by robust clinical trials and a manageable side effect profile.

Explore how a paradigm shift from monoamine to GABAergic systems could offer new, more effective treatments for major depressive disorder; the latest review discusses the unmet needs and the promising potential of NAS GABAA receptor PAMs.

Discover the implications of a newly identified depression subtype, “cognitive biotype,” which not only presents with significant cognitive impairments but also shows resistance to standard antidepressant treatments.

Discover the advancements in MDD pharmacotherapy that promise to expand treatment options and address unmet needs.

The study on the use of subcutaneous racemic ketamine in treatment-resistant depression underscores the significance of a flexible, individualized dosing approach over a 4-week course.